{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:45:39Z","timestamp":1794559539350,"version":"4.9.1"},"reference-count":63,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.autrev.2021.102786","type":"journal-article","created":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T10:14:46Z","timestamp":1613902486000},"page":"102786","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Risk factors for hypertension in rheumatoid arthritis patients\u2013A systematic review"],"prefix":"10.1016","volume":"20","author":[{"given":"Brook","family":"Hadwen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"Stranges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian","family":"Barra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2021.102786_bb0005","first-page":"S128","article-title":"Epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis: a synopsis","volume":"20","author":"Gibofsky","year":"2014","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.autrev.2021.102786_bb0010","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/rheumatology\/kew061","article-title":"Self-reported comorbidity is common in early inflammatory arthritis and associated with poorer function and worse arthritis disease outcomes: results from the Canadian early arthritis cohort","volume":"55","author":"Hitchon","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2021.102786_bb0015","first-page":"S35","article-title":"Mortality in rheumatoid arthritis: 2008 update","volume":"26","author":"Sokka","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2021.102786_bb0020","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1136\/annrheumdis-2011-200726","article-title":"Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies","volume":"71","author":"Avina-Zubieta","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102786_bb0025","doi-asserted-by":"crossref","first-page":"R131","DOI":"10.1186\/ar3442","article-title":"Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study","volume":"13","author":"Innala","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2021.102786_bb0030","first-page":"2562","article-title":"Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset","volume":"26","author":"W\u00e5llberg-Jonsson","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2021.102786_bb0035","first-page":"768","article-title":"The effect of rheumatoid arthritis-associated autoantibodies on the incidence of cardiovascular events in a large inception cohort of early inflammatory arthritis","volume":"56","author":"Barra","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2021.102786_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0117952","article-title":"The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"10","author":"Baghdadi","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2021.102786_bb0045","doi-asserted-by":"crossref","first-page":"rky005","DOI":"10.1093\/rap\/rky005","article-title":"Burden of rheumatoid arthritis among US Medicare population: co-morbidities, health-care resource utilization and costs","volume":"2","author":"Chen","year":"2018","journal-title":"Rheumatol Adv Pract"},{"key":"10.1016\/j.autrev.2021.102786_bb0050","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3899\/jrheum.180668","article-title":"Comorbidities in patients with rheumatoid arthritis and their association with patient-reported outcomes: results of claims data linked to questionnaire survey","volume":"46","author":"Luque Ramos","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2021.102786_bb0055","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/acr.23094","article-title":"Incidence and management of cardiovascular risk factors in psoriatic arthritis and rheumatoid arthritis: a population-based study","volume":"69","author":"Jafri","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2021.102786_bb0060","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s41927-018-0014-y","article-title":"Cardiovascular co-morbidity in patients with rheumatoid arthritis: a narrative review of risk factors, cardiovascular risk assessment and treatment","volume":"2","author":"Jagpal","year":"2018","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.autrev.2021.102786_bb0065","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1093\/rheumatology\/ken159","article-title":"Hypertension in rheumatoid arthritis","volume":"47","author":"Panoulas","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2021.102786_bb0070","author":"Ottawa Hospital Research Institute"},{"key":"10.1016\/j.autrev.2021.102786_bb0075","series-title":"ROB 2: A revised Cochrane risk-of-bias tool for randomized trials","author":"Cochrane Methods","year":"2011"},{"key":"10.1016\/j.autrev.2021.102786_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2014.05.005","article-title":"Evaluation and treatment of cryptorchidism: AUA guideline","author":"Kolon","year":"2014","journal-title":"J Urol."},{"key":"10.1016\/j.autrev.2021.102786_bb0085","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s00296-019-04431-4","article-title":"The impact of cardiorespiratory fitness on classical cardiovascular disease risk factors in rheumatoid arthritis: a cross-sectional and longitudinal study","volume":"39","author":"Cooney","year":"2019","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2021.102786_bb0090","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12891-017-1473-9","article-title":"Sedentary behaviour is associated with increased long-term cardiovascular risk in patients with rheumatoid arthritis independently of moderate-to-vigorous physical activity","volume":"18","author":"Fenton","year":"2017","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.autrev.2021.102786_bb0095","first-page":"203","article-title":"Initiation of disease-modifying therapies in rheumatoid athritis is associated with changes in blood pressure","volume":"24","author":"Baker","year":"2018","journal-title":"J Clin Rheumatol Pract Reports Rheum Musculoskelet Dis"},{"key":"10.1016\/j.autrev.2021.102786_bb0100","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/1529-0131(200109)44:9<1984::AID-ART346>3.0.CO;2-B","article-title":"Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the treatment of rheumatoid arthritis trial Investigator Group","volume":"44","author":"Cohen","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102786_bb0105","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/EDE.0000000000000446","article-title":"Tumor necrosis factor-\u03b1 inhibitor use and the risk of incident hypertension in patients with rheumatoid arthritis","volume":"27","author":"Desai","year":"2016","journal-title":"Epidemiology"},{"key":"10.1016\/j.autrev.2021.102786_bb0110","first-page":"1810","article-title":"Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis--a randomized study","volume":"34","author":"Hafstr\u00f6m","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2021.102786_bb0115","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1053\/j.ajkd.2013.08.010","article-title":"Development of reduced kidney function in rheumatoid arthritis","volume":"63","author":"Hickson","year":"2014","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"key":"10.1016\/j.autrev.2021.102786_bb0120","article-title":"Association between biologic disease modifying anti-rheumatic drugs and incident hypertension in patients with rheumatoid arthritis: results from prospective nationwide KOBIO registry","volume":"99","author":"Kim","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2021.102786_bb0125","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/HJH.0b013e328325d831","article-title":"Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study","volume":"27","author":"Krum","year":"2009","journal-title":"J Hypertens"},{"key":"10.1016\/j.autrev.2021.102786_bb0130","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/1529-0131(200106)45:3<240::AID-ART255>3.0.CO;2-I","article-title":"The effectiveness and toxicity of cyclosporin a in rheumatoid arthritis: longitudinal analysis of a population-based registry","volume":"45","author":"Marra","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102786_bb0135","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.3899\/jrheum.131170","article-title":"Longterm blood pressure variability in patients with rheumatoid arthritis and its effect on cardiovascular events and all-cause mortality in RA: a population-based comparative cohort study","volume":"41","author":"Myasoedova","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2021.102786_bb0140","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00296-019-04303-x","article-title":"Dynamics of body mass index and visceral adiposity index in patients with rheumatoid arthritis treated with tofacitinib","volume":"39","author":"Novikova","year":"2019","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2021.102786_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130709","article-title":"The impact of newer biological disease modifying anti-rheumatic drugs on cardiovascular risk factors: a 12-month longitudinal study in rheumatoid arthritis patients treated with rituximab, Abatacept and Tociliziumab","volume":"10","author":"Provan","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2021.102786_bb0150","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1002\/art.23811","article-title":"The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis","volume":"58","author":"Wolfe","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102786_bb0155","first-page":"237","article-title":"Lifestyle modifications to prevent and control hypertension","volume":"10","author":"Samadian","year":"2016","journal-title":"Iran J Kidney Dis"},{"key":"10.1016\/j.autrev.2021.102786_bb0160","first-page":"233","article-title":"Evidence for exercise training in the management of hypertension in adults","volume":"61","author":"Ghadieh","year":"2015","journal-title":"Can Fam Physician"},{"key":"10.1016\/j.autrev.2021.102786_bb0165","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/acr.22711","article-title":"Association of light-intensity physical activity with lower cardiovascular disease risk burden in rheumatoid arthritis","volume":"68","author":"Khoja","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2021.102786_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146078","article-title":"Sedentary behavior and light physical activity are associated with brachial and central blood pressure in hypertensive patients","volume":"10","author":"Gerage","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2021.102786_bb0175","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/1759720X11436239","article-title":"Protective effect of methotrexate in patients with rheumatoid arthritis and cardiovascular comorbidity","volume":"4","author":"Marks","year":"2012","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.autrev.2021.102786_bb0180","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.2174\/1381612825666191112091700","article-title":"Methotrexate and vasculoprotection: mechanistic insights and potential therapeutic applications in old age","volume":"25","author":"Mangoni","year":"2019","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.autrev.2021.102786_bb0185","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/art.39833","article-title":"Improvement of high-density lipoprotein function in patients with early rheumatoid arthritis treated with methotrexate monotherapy or combination therapies in a randomized controlled trial","volume":"69","author":"Charles-Schoeman","year":"2017","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"10.1016\/j.autrev.2021.102786_bb0190","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1002\/art.24040","article-title":"Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte\/macrophages","volume":"58","author":"Reiss","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102786_bb0195","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2021.102786_bb0200","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/annrheumdis-2017-211836","article-title":"Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"77","author":"Rempenault","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102786_bb0205","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s40266-019-00653-0","article-title":"Cardiovascular disease risk in older adults and elderly patients with rheumatoid arthritis: what role can disease-modifying antirheumatic drugs play in cardiovascular risk reduction?","volume":"36","author":"Day","year":"2019","journal-title":"Drugs Aging"},{"key":"10.1016\/j.autrev.2021.102786_bb0210","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/acr.20371","article-title":"Systematic review and meta-analysis: anti-tumor necrosis factor \u03b1 therapy and cardiovascular events in rheumatoid arthritis","volume":"63","author":"Barnabe","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2021.102786_bb0215","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102786_bb0220","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9051310","article-title":"Effect of dysmetabolisms and comorbidities on the efficacy and safety of biological therapy in chronic inflammatory joint diseases","volume":"9","author":"Cometi","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.autrev.2021.102786_bb0225","doi-asserted-by":"crossref","first-page":"R30","DOI":"10.1186\/ar2383","article-title":"Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study","volume":"10","author":"Naranjo","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2021.102786_bb0230","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007893.pub2","article-title":"Effect of cyclosporine on blood pressure","author":"Robert","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2021.102786_bb0235","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/FJC.0b013e318157f72d","article-title":"COX-2 inhibitors and cardiovascular risk","volume":"50","author":"Funk","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.autrev.2021.102786_bb0240","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1097\/HJH.0b013e3283310dc9","article-title":"Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis","volume":"27","author":"Chan","year":"2009","journal-title":"J Hypertens"},{"key":"10.1016\/j.autrev.2021.102786_bb0245","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/bcp.13048","article-title":"Cardiovascular effects of cyclooxygenase-2 inhibitors: a mechanistic and clinical perspective","volume":"82","author":"Patrono","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.autrev.2021.102786_bb0250","first-page":"505","article-title":"Adverse effects of corticosteroids on the cardiovascular system","volume":"16","author":"Sholter","year":"2000","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.autrev.2021.102786_bb0255","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.bcp.2019.04.009","article-title":"Risks and benefits of corticosteroids in arthritic diseases in the clinic","volume":"165","author":"Petta","year":"2019","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.autrev.2021.102786_bb0260","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.3899\/jrheum.100461","article-title":"Incident comorbidity among patients with rheumatoid arthritis treated or not with low-dose glucocorticoids: a retrospective study","volume":"37","author":"Mazzantini","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2021.102786_bb0265","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jbspin.2010.02.040","article-title":"Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review","volume":"78","author":"Ruyssen-Witrand","year":"2011","journal-title":"Jt Bone Spine"},{"key":"10.1016\/j.autrev.2021.102786_bb0270","article-title":"Oral glucocorticoids and incidence of hypertension in people with chronic inflammatory diseases: a population-based cohort study","volume":"192","author":"Mebrahtu","year":"2020","journal-title":"C Can Med Assoc J = J l\u2019Association Medicale Can"},{"key":"10.1016\/j.autrev.2021.102786_bb0275","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1681\/ASN.2007080911","article-title":"A critical role for vascular smooth muscle in acute glucocorticoid-induced hypertension","volume":"19","author":"Goodwin","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2021.102786_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102371","article-title":"Systemic lupus erythematosus and hypertension","volume":"18","author":"Munguia-Realpozo","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102786_bb0285","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/art.39098","article-title":"Disease activity in rheumatoid arthritis and the risk of cardiovascular events","volume":"67","author":"Solomon","year":"2015","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"10.1016\/j.autrev.2021.102786_bb0290","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2478\/jtim-2020-0015","article-title":"Metabolic syndrome and atherogenic indices in rheumatoid arthritis and their relationship with disease activity: a hospital-based study from Northeast India","volume":"8","author":"Bhattacharya","year":"2020","journal-title":"J Transl Intern Med"},{"key":"10.1016\/j.autrev.2021.102786_bb0295","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.autrev.2018.02.007","article-title":"Impact of obesity on autoimmune arthritis and its cardiovascular complications","volume":"17","author":"Van Raemdonck","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102786_bb0300","doi-asserted-by":"crossref","first-page":"k1036","DOI":"10.1136\/bmj.k1036","article-title":"Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications","volume":"361","author":"England","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2021.102786_bb0305","article-title":"Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout","author":"Hansildaar","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2021.102786_bb0310","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/acr.21710","article-title":"Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: a long-term followup from disease onset","volume":"65","author":"Ajeganova","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2021.102786_bb0315","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s42358-019-0089-1","article-title":"High prevalence of obesity in rheumatoid arthritis patients: association with disease activity, hypertension, dyslipidemia and diabetes, a multi-center study","volume":"59","author":"de Resende Guimar\u00e3es","year":"2019","journal-title":"Adv Rheumatol (London, England)"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997221000495?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997221000495?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:22:33Z","timestamp":1761600153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997221000495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S1568997221000495"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2021.102786","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factors for hypertension in rheumatoid arthritis patients\u2013A systematic review","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2021.102786","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102786"}}